Key Highlights
- Organigram Global (NASDAQ:OGI) reported third quarter fiscal 2026 Net Income of CAD 105.5 million on August 11, 2026, against a CAD 6.3 million loss a year earlier, mainly from non-cash Fair Value gains on preferred shares.
- Net Revenue was CAD 105.8 million, up 49%, and adjusted EBITDA was CAD 13.4 million, up 136% from CAD 5.7 million, for the quarter ended June 30, 2026.
- Published market data lists a 1 year EPS change of 821.77%, which comes from a loss-making base and a fair value gain, not from operating profit.
- Cash and short-term investments were CAD 11.7 million, Liquidity including Credit facilities was CAD 49.1 million, and total liabilities were CAD 334.8 million.
Fair Value Gains Drive the Headline Profit
Organigram Global (NASDAQ:OGI) is a Canadian cannabis producer. Its third quarter net income of CAD 105.5 million came mainly from non-cash gains on the fair value of preferred shares, which are not core operations. When a Liability or instrument is remeasured, a lower value is booked as a gain, and the effect can reverse later. Adjusted EBITDA of CAD 13.4 million is a cleaner guide to operations. The release does not name the currency, and Organigram reports in Canadian dollars. By simple arithmetic, adjusted EBITDA was about 12.7% of net revenue, while net income was roughly equal to net revenue, which shows how unusual the gain is.
Sanity Group Deal Lifts Revenue and Market Share
The Sanity Group Acquisition closed on April 15, 2026 and contributed about CAD 40 million of net revenue in the quarter. Adjusted gross Margin was CAD 39.1 million, or 37% of net revenue, and selling, general and administrative expense was CAD 32.7 million. Management said it remains on track for fiscal year net revenue above CAD 350 million. Company data show the first rank in Canada for vapes, milled flower and concentrates as of June 2026, and second place in flower and pre-rolls. Edibles ranked third and beverages fourth. The acquisition also brought German exposure and integration work.
The 821.77% Caveat, Cash Flow and a CFO Exit
The 821.77% EPS change is published market data and is unverified. Growth from a negative base looks extreme, and here the swing from a CAD 6.3 million loss to a gain driven by fair value is likely to be GAAP, not adjusted, though the basis is not confirmed. Free cash flow was negative CAD 3.9 million and Operating Cash Flow negative CAD 4.3 million. Total liabilities rose from CAD 213.1 million at September 30, 2025, and CFO Paolo De Luca is departing.
Where Things Stand
Largely no. The 821.77% EPS jump mostly reflects a non-cash fair value gain measured against a loss-making base, not a nearly ninefold rise in operating earnings. Organigram Global (NASDAQ:OGI) does show real operating progress, with net revenue up 49%, adjusted EBITDA up 136% and a larger Canadian footprint after the Sanity Group deal, but cash flow was negative and liabilities rose. Investors may watch the fiscal fourth quarter report, which has no confirmed date, along with free cash flow, the CFO succession, progress on integrating the Sanity Group Business and whether fair value gains reverse. Management has said fiscal net revenue should exceed CAD 350 million, a target that is not a guarantee. Because the comparison base will no longer be a loss, a repeat of this EPS change is unlikely in future quarters.
_11_16_2026_20_28_14_334128.jpg)





Please wait processing your request...